Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin

Clinical Pharmacokinetics

Volumn 43, Issue 6, 2004, Pages 395-404

  Conte Jr , John E ^a,b   Golden, Jeffrey A ^a   Kipps, Juliana E ^a   Lin, Emil T ^b   Zurlinden, Elisabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; SAQUINAVIR; STAVUDINE; UREA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; FEVER; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ALVEOLUS CELL; LUNG LAVAGE; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SMOKING; STATISTICAL SIGNIFICANCE; THORAX DISEASE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; HUMANS; LUNG; MALE; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; RESPIRATORY MUCOSA; RIFAMPIN; SEX FACTORS; TISSUE DISTRIBUTION;

EID: 2342548278     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443060-00003     Document Type: Article

References (40)

1. Anon. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-20): 1-58
2. Peloquin CA, Jaresko GS, Yong CL, et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41 (12): 2670-9
3. Acocella G, Nonis A, Perna G, et al. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy: II. two-month, daily administration study. Am Rev Respir Dis 1988; 138 (4): 886-90
4. Berning SE, Huitt GA, Iseman MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992; 327 (25): 1817-8
5. Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3 (11 Suppl. 3): S301-8
6. Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16 (3): 717-29
7. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30 (9): 919-25
8. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993; 329 (15): 1122-3
9. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127 (4): 289-93
10. Gordon SM, Horsburgh Jr CR, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993; 168 (6): 1559-62
11. Jaruratanasirikul S. The pharmacokinetics of oral rifampicin in AIDS patients. J Med Assoc Thai 1998; 81 (1): 25-8
12. Choudhri SH, Hawken M, Gathua S, et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997; 25 (1): 104-11
13. Acocella G, Carlone NA, Cuffini AM, et al. The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages. Am Rev Respir Dis 1985; 132 (6): 1268-73
14. Dhillon J, Mitchison DA. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992; 145 (1): 212-4
15. Mor N, Simon B, Mezo N, et al. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995; 39 (9): 2073-7
16. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33 (3): 167-75
17. Crowle AJ, Elkins N, May MH. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988; 137 (5): 1141-6
18. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36 (6): 1171-5
19. Baldwin DR, Maxwell SR, Honeybourne D, et al. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 1991; 28 (1): 79-86
20. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3 (8): 886-90
21. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30 (3): 249-60
22. Conte JEJ, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40 (7): 1617-22
23. Conte JEJ, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995; 39 (2): 334-8
24. Conte Jr JE, Golden JA, Duncan S, et al. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43 (6): 1329-33
25. Conte Jr JE, Golden JA, McQuitty M, et al. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations. Antimicrob Agents Chemother 2000; 44 (5): 1337-41
26. Conte Jr JE, Golden JA, McQuitty M, et al. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Antimicrob Agents Chemother 2000; 44 (4): 985-90
27. Ziglam HM, Baldwin DR, Daniels I, et al. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 2002; 50 (6): 1011-5
28. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60 (2): 532-8
29. Marcy TW, Merrill WW, Rankin JA, et al. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987; 135 (6): 1276-80
30. Effros RM, Feng NH, Mason G, et al. Solute concentrations of the pulmonary epithelial lining fluid of anesthetized rats. J Appl Physiol 1990; 68 (1): 275-81
31. Baldwin DR, Wise R, Andrews JM, et al. The distribution of temafloxacin in bronchial epithelial lining fluid, alveolar macrophages and bronchial mucosa. Eur Respir J 1992; 5 (4): 471-6
32. Von Wichert P, Joseph K, Muller B, et al. Bronchoalveolar lavage: quantitation of intraalveolar fluid? Am Rev Respir Dis 1993; 147 (1): 148-52
33. Conte Jr JE, Lin E, Zurlinden E. Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. J Chromatogr Sci 2000; 38 (2): 72-6
34. Talke HSGE. Enzymatische harnstoffbestimmung im blut und serum im optischem test nach warburg. Klin Wochenschr 1965; 43: 174
35. Willcox M, Kervitsky A, Watters LC, et al. Quantification of cells recovered by bronchoalveolar lavage: comparison of cytocentrifuge preparations with the filter method. Am Rev J Respir Dis 1988; 138 (1): 74-80
36. Anon. 1983 Metropolitan height and weight tables. Stat Bull 1983; 64: 2-9
37. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269 (6): 729-30
38. Lee CN, Heifets LB. Determination of minimal inhibitory concentrations of antitubercolosis drugs by radiometric and conventional methods. Am Rev Respir Dis 1987; 136 (2): 349-52
39. Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids [published erratum appears in Chest 1999 May; 115 (5): 1485]. Chest 1999; 115 (1): 12-8
40. Hand WL, Boozer RM, King-Thompson NL. Antibiotic uptake by alveolar macrophages of smokers. Antimicrob Agents Chemother 1985; 27 (1): 42-5